Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Vroege voeding versus vertraagde voeding na colorectale endoscopische submucosale dissectie

18 september 2026 bijgewerkt door: Seung Min Hong, Pusan National University Hospital

Vergelijking van klinische resultaten volgens de timing van herstart in de voeding na colorectale endoscopische submucosale dissectie: een prospectieve, multicenter, gerandomiseerde gecontroleerde studie

Currently, there are no clear guidelines regarding the optimal timing for dietary restart after gastrointestinal endoscopic submucosal dissection (ESD). While several studies have addressed upper gastrointestinal ESD, a meta-analysis reported that early feeding, initiated within one day after the procedure, showed no statistically significant difference in complication rates compared to delayed feeding initiated after two or more days. Moreover, early feeding was associated with shorter hospital stays and higher patient satisfaction. However, to the best of our knowledge, no studies have investigated early feeding in colorectal ESD.

On the other hand, in the context of surgical procedures involving the gastrointestinal tract, several studies suggest that early feeding may offer clinical advantages over delayed feeding.

The aim of this study is to explore the optimal timing for dietary restart following colorectal ESD. In the early feeding group (<24 hours), patients begin water intake if no abnormalities are observed during a follow-up examination conducted two hours post-procedure. If no further issues arise after an additional two hours, a liquid diet is initiated. In contrast, the delayed feeding group (>24 hours) maintains fasting on the day of the procedure and begins a liquid diet the following day. The study will compare the early and delayed feeding groups in terms of early post-procedural adverse events (occurring within 24 hours after the procedure)(e.g., bleeding, perforation, post-coagulation syndrome), patient satisfaction, and delayed post-procedural adverse events (occurring more than 24 hours after the procedure).

Studie Overzicht

Gedetailleerde beschrijving

● Sample Size Calculation: This study was designed as a non-inferiority trial. The expected incidence of post-procedural adverse events was assumed to be 1.5% in both groups. Sample size estimation was performed using PASS version 11, assuming a non-inferiority margin of 5%, a one-sided alpha level of 0.025, and 80% power. Based on these assumptions, 96 patients were required per group. After allowing for a 5% dropout rate, the final target enrollment was set at 102 patients per group, resulting in a total sample size of 204 patients.

● Randomization and Blinding: This clinical study employs block randomization to allocate participants to the experimental group (early diet resumption, EDR) and the control group (delayed diet resumption, DDR) in a 1:1 ratio. Blinding will not be applied. A randomization table will be generated independently by a statistician from the Medical Statistics Department of Pusan National University Hospital, using the blockrand package in R (version 4.3.3; R Core Team, 2024, http://cran.r-project.org). The block size will remain blinded.

● Research Participation Procedure: After signing the consent form, the admission process is initiated. Basic tests such as blood tests, ECG, and chest/abdominal X-rays are conducted. Fasting and bowel preparation are performed the day before the procedure.

● Procedure and Initial Management: On the day of the procedure, both groups undergo standard colorectal ESD. Two hours after the procedure, a physical examination, CBC, and chest/abdominal X-rays are performed.

● Dietary Group Classification: Early Feeding Group: If no abnormalities are found during the examination 2 hours after the procedure, water intake begins, followed by a liquid diet and then a porridge diet if no complications occur.

Late Feeding Group: Patients remain fasting on the day of the procedure. A liquid diet begins 24 hours after the procedure, followed by a porridge diet if no complications occur.

● Survey: Patient satisfaction is evaluated through a survey. Patients visit the outpatient clinic after discharge to review procedural outcomes and assess for delayed complications.

● Observation Items: Age, sex, height, weight, BMI, underlying diseases (hypertension, diabetes, cerebrovascular disease, ischemic heart disease, other heart diseases, atrial fibrillation (or atrial flutter), other arrhythmias, chronic kidney disease, dialysis status, liver cirrhosis, other vascular diseases), history of previous abdominal surgery, smoking history, alcohol consumption history, medication history (aspirin, clopidogrel, other antithrombotic agents, warfarin, direct oral anticoagulants (DOACs), nonsteroidal anti-inflammatory drugs (NSAIDs), steroids), type of bowel preparation used, pre-procedure serum white blood cell count, pre-procedure serum hemoglobin, pre-procedure serum platelet count, pre-procedure absolute neutrophil count, pre-procedure prothrombin time (PT) (including INR), pre-procedure activated partial thromboplastin time (aPTT), post-procedure serum white blood cell count, post-procedure serum hemoglobin, post-procedure serum platelet count, post-procedure absolute neutrophil count, location of the lesion, size of the lesion (long axis, short axis), macroscopic morphology of the lesion, degree of submucosal fibrosis, resection method, resection time, post-resection management time, total procedure time, type of post-resection management performed, en bloc resection status, occurrence of complications during the procedure, measures taken for intra-procedural complications and their outcomes, occurrence of complications within 24 hours post-procedure, measures taken for complications within 24 hours post-procedure and their outcomes, occurrence of complications beyond 24 hours post-procedure, measures taken for complications beyond 24 hours post-procedure and their outcomes, length of hospital stay (days), pathology results (histology, differentiation grade, invasion depth, horizontal resection margin, vertical resection margin, lymphatic invasion, vascular invasion, perineural invasion), number of days until outpatient follow-up after discharge, patient satisfaction (Likert scale).

● Data Analysis and Statistical Methods: All statistical analyses were conducted using R software, version 4.5.3 (R Foundation for Statistical Computing, Vienna, Austria). The fmsb package was used to estimate risk differences and mean differences (MDs). Continuous data were summarized as mean ± standard deviation or median with interquartile range, depending on their distribution. Categorical data were summarized as number and percentage. Comparisons between the two groups were made using the independent t-test or Wilcoxon rank-sum test for continuous variables and the chi-square test or Fisher's exact test for categorical variables, as appropriate.

In the non-inferiority analysis, the treatment effect was expressed as the difference between the EDR and DDR groups, defined as EDR minus DDR. Two-sided 95% confidence intervals (CIs) were calculated for the risk differences. EDR was considered non-inferior to DDR for post-procedural adverse events when the upper limit of the 95% CI was below the prespecified non-inferiority margin of 5%. To evaluate potential factors associated with post-procedural adverse events, logistic regression analyses were performed. Variables considered clinically relevant and showing an association with adverse events in univariable analysis at p < 0.20 were selected for inclusion in the multivariable model.

A one-sided alpha level of 0.025 was applied for the non-inferiority test. For all other analyses, two-sided p values < 0.05 were considered statistically significant. Missing data were not imputed.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

204

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Busan, Zuid -Korea, 49241
        • Pusan National University Hospital
      • Busan, Zuid -Korea, 47392
        • Inje university busan paik hospital
      • Busan, Zuid -Korea, 49267
        • Kosin university gospel hospital
      • Ulsan, Zuid -Korea, 44033
        • Ulsan university hospital
      • Yangsan, Zuid -Korea, 50612
        • Pusan National University Yangsan Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

19 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Eligible patients were adults (≥19 years) scheduled to undergo colorectal ESD who met one or more of the following indications:

  • Differentiated early colorectal cancer ≤5 cm without ulceration and confined to the mucosa
  • Laterally spreading tumor ≥2 cm
  • Sessile polyp ≥2 cm
  • Adenoma with fibrosis
  • Differentiated early colorectal cancer without lymph node metastasis
  • Colorectal subepithelial lesion These indications correspond to the reimbursement criteria for colorectal ESD under the Korean National Health Insurance system.

The exclusion criteria were as follows:

  • Untreated colorectal cancer
  • Active inflammatory bowel disease
  • Coagulopathy or prothrombin time-international normalized ratio >1.5 despite medical correction, pregnancy
  • Endoscopically unmanageable perforation or bleeding during the procedure
  • Refusal to provide informed consent

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Early feeding group

The group implementing early feeding (< 24hr).

Begin drinking water 2 hours after the procedure. If no complications occur 2 hours after starting water intake, progress to a liquid diet. If no abnormalities are observed after the liquid diet, transition to a soft diet for the next meal.

Actieve vergelijker: Late feeding group

The group implementing late feeding (> 24hr).

Maintain fasting on the day of the procedure. Begin a liquid diet 24 hours after the procedure. If no complications occur after starting the liquid diet, transition to a soft diet at the next meal.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
early post-procedural adverse events occurring within 24 hours after the procedure
Tijdsspanne: Through study completion, an average of 1 year

Bleeding, perforation, Post procedural coagulation syndrome

Through study completion, an average of 1 year

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
delayed post-procedural adverse events occurring more than 24 hours after the procedure
Tijdsspanne: Through study completion, an average of 1 year

Bleeding, perforation, Post procedural coagulation syndrome

Through study completion, an average of 1 year
patient satisfaction
Tijdsspanne: through study completion, an average of 1 year

Patient satisfaction is assessed through a survey conducted with the patients.

through study completion, an average of 1 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Dong Hoon Baek, MD, PhD, Pusan National University Hospital

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

1 februari 2025

Primaire voltooiing (Werkelijk)

1 februari 2026

Studie voltooiing (Werkelijk)

28 februari 2026

Studieregistratiedata

Eerst ingediend

18 januari 2025

Eerst ingediend dat voldeed aan de QC-criteria

27 januari 2025

Eerst geplaatst (Werkelijk)

3 februari 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

23 september 2026

Laatste update ingediend die voldeed aan QC-criteria

18 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren